Mitsubishi UFJ Asset Management Co. Ltd. Buys New Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, HoldingsChannel reports. The fund purchased 50,907 shares of the company’s stock, valued at approximately $1,356,000.

Several other hedge funds also recently made changes to their positions in the business. Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $28,000. Raleigh Capital Management Inc. grew its stake in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. increased its position in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, US Bancorp DE boosted its holdings in shares of Hims & Hers Health by 346.7% in the 4th quarter. US Bancorp DE now owns 1,943 shares of the company’s stock valued at $47,000 after buying an additional 1,508 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on HIMS. Morgan Stanley lowered shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Leerink Partners raised their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday, February 25th. Needham & Company LLC boosted their price target on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Bank of America raised their price objective on Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research report on Tuesday, March 18th. Finally, Citigroup reissued a “sell” rating and set a $27.00 target price on shares of Hims & Hers Health in a report on Thursday, March 6th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $37.31.

Hims & Hers Health Stock Up 0.4 %

NYSE HIMS opened at $31.16 on Thursday. The firm has a 50-day moving average price of $39.97 and a two-hundred day moving average price of $29.79. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98. The company has a market capitalization of $6.92 billion, a P/E ratio of 70.82 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 7,259 shares of the firm’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $24.07, for a total value of $174,724.13. Following the sale, the insider now directly owns 193,601 shares of the company’s stock, valued at $4,659,976.07. This trade represents a 3.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Soleil Boughton sold 4,152 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now directly owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. The trade was a 2.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,064,954 shares of company stock valued at $37,984,259 in the last ninety days. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.